Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing
Reexamination Certificate
2002-04-25
2008-03-18
Bunner, Bridget E (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C514S002600, C424S184100, C530S300000, C530S350000
Reexamination Certificate
active
07345018
ABSTRACT:
The invention relates to agents for the prevention of organ damage, in particular of the kidneys and the inner ear, induced by the administration of aminoglycosides. Agents according to the invention are all substances which are megalin and/or cubilin antagonists (inhibitors). In particular, these are molecules (compounds) having polybasic structures which bind to megalin and inhibit the binding of aminoglycosides and related substances.
REFERENCES:
patent: 4122171 (1978-10-01), Niizato et al.
patent: 4526888 (1985-07-01), Williams et al.
patent: 4554101 (1985-11-01), Hopp
patent: 4654325 (1987-03-01), Selenke
patent: 5039666 (1991-08-01), Novick, Jr.
patent: 5059591 (1991-10-01), Janoff et al.
patent: 5079234 (1992-01-01), McGregor et al.
patent: 5087441 (1992-02-01), Elfarra
patent: 5409704 (1995-04-01), Bally et al.
patent: 5731320 (1998-03-01), Wagner et al.
patent: 5773444 (1998-06-01), Ahn et al.
patent: 6130217 (2000-10-01), Arnold et al.
patent: 6177434 (2001-01-01), Kopke et al.
patent: 6180604 (2001-01-01), Fraser et al.
patent: 6211234 (2001-04-01), Astles et al.
patent: 6380356 (2002-04-01), Griffin et al.
patent: 6462194 (2002-10-01), Winn et al.
patent: 6645983 (2003-11-01), Joseph et al.
patent: 2002/0132795 (2002-09-01), Stogniew et al.
patent: 0 473 145 (1992-03-01), None
patent: 0 483 634 (1992-05-01), None
patent: 1 364 521 (1974-08-01), None
patent: WO 88/04925 (1988-07-01), None
patent: WO 89/05637 (1989-06-01), None
patent: WO 99/02145 (1999-01-01), None
patent: WO 99/37757 (1999-07-01), None
patent: WO 00/57871 (2000-10-01), None
patent: WO 01/05383 (2001-01-01), None
patent: WO 01/12607 (2001-02-01), None
patent: WO 01/87853 (2001-11-01), None
patent: WO 02/053519 (2002-07-01), None
patent: WO 03/066572 (2003-08-01), None
patent: WO-2003/080103 (2003-10-01), None
Ilso et al. Megalin and cubilib: synergistic endocytic receptors in renal proximal tubule. Am J Physiol Renal Physiol 280: F562 F573, 2001.
Nagai et al. Role of megalin in renal handling of aminoglycosides. Am J Physiol Renal Physiol 281: F337-F334, 2001.
Josepovitz et al. Inhibition of gentamicin uptake in rat renal cortex in vivo by aminoglycosides and organic polycations. J Pharmacol Exp Ther. 223(2):314-321, 1982.
Forge et al. Aminoglycoside antibiotics. Audiology and Neurootology 5: 3-22, 2000.
Melman et al. High affinity binding of receptor-associated protein to heparin and low density lipoprotein receptor-related protein requires similar basic amino acid sequence motifs. J Biol Chem 276(31): 29338-29346, 2001.
Evans et al. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Annals of Pharmacol 33: 960-967, 1999.
Ouderkirk et al. Polymyxin B nephrotoxicity and efficacy against Nosocomial infections caused by multiresistant gram-negative bacteria. AntiMicrob Agents Chemotherapy 47(8): 2659-2662, 2003.
Williams et al. Inhibition of renal membrane binding and nephrotoxicity of aminoglycosides. J Pharmacol Exp Therap 237(3): 919925, 1986.
Watanabe et al. Targeted prevention of renal accumulation and toxicity of gentamicin by aminoglycoside binding receptor antagonists. J Controlled Release 95: 423-433, 2004.
Dowling, R.B., and Wilson, R., “Pseudomonas aeruginosaRespiratory Infections,”Clin. Pulm. Med.6:278-286, Williams & Wilkins (1999).
Begg, E.J. and Barclay, M.L., “Aminoglycosides—50 years on,”Br. J. Clin. Pharmacol. 39:597-603, Blackwell Science Ltd., (1995).
Burton, M.E. et al., “Comparison of drug dosing methods,”Clin. Pharmacokinetics 10:1-37, ADIS Press Limited, (1985).
Christensen, E.I. and Willnow, T.E., “Essential role of megalin in renal proximal tubule for vitamin homoestasis,”J. Am. Soc. Nephrol. 10:2224-2236, American Society of Nephrology, (Oct. 1999).
Decorti, G. et al., “Endocytosis of gentamicin in a proximal tubular renal cell line,”Life Sci. 65:1115-1124, Elsevier Science, Inc., (Aug. 1999).
Ernfors, P. et al., “Protection of auditory neurons from aminoglycoside toxicity by neurotropin-3,”Nat. Med., 2:463-267, Nature Publishing Co., (1996).
Ford, D.M. et al., “Apically and basolaterally internalized anminoglycosides colocalize in LLC-PK1lysosomes and alter cell function,”Am. J. Physiol., 266:C52-57, American Physiological Society, (1994).
Kyte, J. and Doolittle, R.F., “A simple method for displaying the hydropathic character of a protein,”J. Mol. Biol., 157:105-132, Academic Press, Inc. (London) Ltd., (1982).
Lee, S.M. et al., “Nitrendipine protects against animoglycoside nephrotoxicity in the rat,”J. Cardiovasc. Pharmacol., 9 (Suppl. 1) :S65-S69, Raven Press Books, Ltd., (1987).
Moestrup, S.K. et al., “Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs,”J. Clin. Invest., 96:1404-1413, The American Society for Clinical Investigation, Inc., (1995).
Nykjaer, A. et al., “An endocytic pathway essential for renal uptake and activation of the steroid 25- (OH) vitamin D3,”Cell, 96:507-515, Cell Press, (Feb. 1999).
Schacht, J., “Aminoglycoside ototoxicity: prevention in sight?”Otolaryngol. Head Neck Surg., 118:674-677, Mosby Press, (1998).
Schmitz, C. et al., “Megalin deficiency offers protection from renal aminoglycoside accumulation,”J. Biol. Chem., 277:618-622, The American Society for Biochemistry and Molecular Biology, Inc., (Jan. 2002).
Willnow, T.E. et al., “Functional expression of low density lipoprotein receptor-related protein is controlled by receptor-associated protein in vivo,”Proc. Natl. Acad. Sci. USA, 92:4537-4541, National Academy of Sciences, (1995).
Willnow, T.E. et al., “Low density lipoprotein receptor-related protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance,”J. Biol. Chem., 267:26172-26180, The American Society for Biochemistry and Molecular Biology, Inc., (1992).
Willnow, T.E. et al., “Molecular Dissection of ligand binding sites on the low density lipoprotein receptor-related protein,”J. Biol. Chem., 269:15827-15832, The American Society for Biochemistry and Molecular Biology, Inc., (1994).
Willnow, T.E. et al., “RAP, a specialized chaperone, prevents ligand-induced ER retention and degredation of LDL receptor-related endocytic receptors,”EMBO J., 15:2632-2639, Oxford University Press, (1996).
Xuan, W. et al., “Effects of compound injection ofPyrola rotundifoliaL andAstragalus membranaceusBGE on experimental guinea pigs' gentamycin ototoxicity,”Ann. Otol. Rhinol. Laryngol., 104:374-380, Annals Publishing Company, (1995).
Girton, R.A. et al., “Clusterin protects renal tubular epithelial cells from gentamicin-mediated cytotoxicity,”Am. J. Physiol. Renal Physiol. 282:F709-F709, American Physiological Society, (2002; published online Dec. 4, 2001).
Hjalm, G. et al., “Cloning and sequencing of human gp330, a Ca(2+)-binding receptor with potential intracellular signaling properties,”Eur. J. Biochem. 239:132-137, Blackwell Science Ltd., (1996).
Genbank Accession No. XM—003315, “Homo sapienslow density lipoprotein-related protein-associated protein 1 (alpha-2-macroglobulin receptor-associated protein 1) (LRPAP1), mRNA,” Direct submission, National Center for Biotechnology Information, NIH, Bethesda, MD 20894, (Oct. 2001).
Genbank Accession No. XM—011904, “Homo sapienscubilin (intrinsic factor-cobalamin receptor) (CUBN), mRNA,” Direct submission, National Center for Biotechnology Information, NIH, Bethesda, MD 20894, (May 2002).
Genbank Accession No. U33837, Hjalm, G. et al., “Human glycoprotein receptor gp330 precursor, mRNA, complete cds,”, Jan. 31, 1997.
Edwards, M.L., et al., “Polyamine Analogues with Antitumor Activity,”J. Med. Chem. 33:1369-1375, American Chemical Society (1990).
Fan, D., et al., “Reversal of
Bunner Bridget E
Cooper Iver P.
Reception ApS
LandOfFree
Method of treating side effects induced by therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating side effects induced by therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating side effects induced by therapeutic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3977647